HC Wainwright Cuts Relay Therapeutics (NASDAQ:RLAY) Price Target to $14.00

Relay Therapeutics (NASDAQ:RLAY) had its target price lowered by HC Wainwright from $16.00 to $14.00 in a report released on Tuesday, Marketbeat.com reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Relay Therapeutics’ Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.62) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.63) EPS.

A number of other brokerages have also recently weighed in on RLAY. Guggenheim reduced their price target on Relay Therapeutics from $30.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Raymond James Financial reduced their target price on Relay Therapeutics from $29.00 to $19.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.08.

Relay Therapeutics Stock Performance

NASDAQ:RLAY opened at $3.69 on Tuesday. The stock’s 50 day moving average price is $3.52 and its 200 day moving average price is $3.26. Relay Therapeutics has a 52 week low of $1.77 and a 52 week high of $10.72. The company has a market capitalization of $636.20 million, a P/E ratio of -1.89 and a beta of 1.62.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.08. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.07 million. As a group, sell-side analysts forecast that Relay Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, CEO Sanjiv Patel sold 61,379 shares of Relay Therapeutics stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $3.57, for a total value of $219,123.03. Following the transaction, the chief executive officer directly owned 765,288 shares of the company’s stock, valued at $2,732,078.16. The trade was a 7.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Donald A. Bergstrom sold 26,701 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $3.68, for a total value of $98,259.68. Following the completion of the transaction, the insider directly owned 552,720 shares in the company, valued at approximately $2,034,009.60. This represents a 4.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 149,226 shares of company stock worth $542,926 in the last ninety days. 4.87% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Commodore Capital LP bought a new position in Relay Therapeutics during the second quarter valued at about $46,191,000. Bellevue Group AG increased its position in shares of Relay Therapeutics by 11.6% during the second quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock valued at $28,479,000 after purchasing an additional 853,578 shares during the period. Tang Capital Management LLC increased its position in shares of Relay Therapeutics by 126.1% during the fourth quarter. Tang Capital Management LLC now owns 8,068,058 shares of the company’s stock valued at $33,240,000 after purchasing an additional 4,500,000 shares during the period. Geode Capital Management LLC increased its position in shares of Relay Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock valued at $11,176,000 after purchasing an additional 159,548 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Relay Therapeutics by 69.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,964,997 shares of the company’s stock valued at $12,216,000 after purchasing an additional 1,216,334 shares during the period. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.